1. Adelaide Research & Scholarship

Search


Current filters:

Start a new search
Add filters:

Use filters to refine the search results.

 | 
Results 1-10 of 64 (Search time: 0.002 seconds).
Item hits:
PreviewIssue DateTitleAuthor(s)
2008Is drug treatment superior to allografting as first-line therapy in chronic myeloid leukemia?Hughes, T.
2004Oral versus intravenous ganciclovir for the prophylaxis of cytomegalovirus disease after allogeneic bone marrow transplantationSzer, J.; Durrant, S.; Schwarer, A.; Bradstock, K.; Gibson, J.; Arthur, C.; To, L.; Hughes, T.; Raunow, H.
2004Interferon-α-2b and oral cytarabine ocfosfate for newly diagnosed chronic myeloid leukaemiaMollee, P.; Arthur, C.; Hughes, T.; Januszewicz, H.; Grigg, A.; Bradstock, K.; Wolf, M.; Gibson, J.; Schwarer, A.; Spencer, A.; Browett, P.; Hawkins, T.; Seldon, M.; Herrmann, R.; Watson, A.; Seymour, J.; Martin, N.; Shina, S.; Low, C.; Wright, S.; et al.
2000A new rare t(9;11)(p22;p15) in acute leukaemiaNicola, M.; Suttle, J.; Beerworth, J.; Dobrovic, A.; Hughes, T.; Moore, S.
2002Mannose-binding lectin gene polymorphisms are associated with major infection following allogeneic hemopoietic stem cell transplantationMullighan, C.; Heatley, S.; Doherty, K.; Szabo, F.; Grigg, A.; Hughes, T.; Schwarer, A.; Szer, J.; Tait, B.; To, L.; Bardy, P.
2002Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistantFrost, M.; Ferrao, P.; Hughes, T.; Ashman, L.
2003Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phaseBranford, S.; Rudzki, Z.; Harper, A.; Grigg, A.; Taylor, K.; Durrant, S.; Arthur, C.; Browett, P.; Schwarer, A.; Ma, D.; Seymour, J.; Bradstock, K.; Joske, D.; Lynch, K.; Gathmann, I.; Hughes, T.
2002High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistanceBranford, S.; Rudzki, Z.; Walsh, S.; Grigg, A.; Arthur, C.; Taylor, K.; Herrmann, R.; Lynch, K.; Hughes, T.
2007Monitoring disease responseHughes, T.; Branford, S.; Melo, J.; Goldman, J.
2006Five-year follow-up of patients receiving imatinib for chronic myeloid leukemiaDruker, B.; Guilhot, F.; O'Brien, S.; Gathmann, I.; Kantarjian, H.; Gattermann, N.; Deininger, M.; Silver, R.; Goldman, J.; Stone, R.; Cervantes, F.; Hochhaus, A.; Powell, B.; Gabrilove, J.; Rousselot, P.; Reiffers, J.; Cornelissen, J.; Hughes, T.; Agis, H.; Fischer, T.; et al.

Discover